menu
    • menu
    [{"orgOrder":0,"company":"IntoCell","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Phospholipid Drug Conjugates","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"IntoCell \/ Cellectar"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IntoCell \/ ADC Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by IntoCell

    Menu

    IntoCell

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IntoCell

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            IntoCell

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Sponsor : ADC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IntoCell Enters into Development and License Option Agreement with ADC Therapeutics

                            Details : ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Antibody

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Sponsor : ADC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IntoCell

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            IntoCell

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phospholipid Drug Conjugates

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc

                            Details : The collaboration focuses on combining IntoCell’s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 13, 2021

                            Lead Product(s) : Phospholipid Drug Conjugates

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth